Increased wild-type N-ras activation by neurofibromin down-regulation increases human neuroblastoma stem cell malignancy.

PubWeight™: 0.76‹?›

🔗 View Article (PMC 3379567)

Published in Genes Cancer on November 01, 2011

Authors

Dan Han1, Barbara A Spengler, Robert A Ross

Author Affiliations

1: Department of Biological Sciences, Fordham University, Bronx, NY, USA.

Articles cited by this

Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature (1983) 19.76

Tumour stem cells and drug resistance. Nat Rev Cancer (2005) 15.21

Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer (2003) 15.17

Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science (1984) 9.64

RAS oncogenes: the first 30 years. Nat Rev Cancer (2003) 8.61

Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas. J Natl Cancer Inst (1984) 4.01

The ras gene family and human carcinogenesis. Mutat Res (1988) 3.20

Tools of the trade: use of dominant-inhibitory mutants of Ras-family GTPases. Nat Cell Biol (1999) 3.18

Malignancy in neurofibromatosis type 1. Oncologist (2000) 2.78

Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell (2009) 2.73

Ras in cancer and developmental diseases. Genes Cancer (2011) 2.68

Cancer stem cells in radiation resistance. Cancer Res (2007) 2.59

Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res (1989) 2.19

NF1 is a tumor suppressor in neuroblastoma that determines retinoic acid response and disease outcome. Cell (2010) 1.81

Characteristics of stem cells from human neuroblastoma cell lines and in tumors. Neoplasia (2005) 1.75

Dynamic regulation of the Ras pathway via proteolysis of the NF1 tumor suppressor. Genes Dev (2003) 1.64

Identification of the neurofibromatosis type 1 gene product. Proc Natl Acad Sci U S A (1991) 1.55

Human neuroblastoma I-type cells are malignant neural crest stem cells. Cell Growth Differ (1995) 1.52

Neurofibromatosis type 1 gene mutations in neuroblastoma. Nat Genet (1993) 1.48

Coordinate changes in neuronal phenotype and surface antigen expression in human neuroblastoma cell variants. Cancer Res (1987) 1.47

Ras isoform abundance and signalling in human cancer cell lines. Oncogene (2007) 1.30

Isoform-specific ras functions in development and cancer. Future Oncol (2009) 1.29

Control of stemness by fibroblast growth factor signaling in stem cells and cancer stem cells. Curr Stem Cell Res Ther (2009) 1.25

Characterization of human neuroblastoma cell lines established before and after therapy. J Natl Cancer Inst (1986) 1.22

Proteasome inhibitors up-regulate haem oxygenase-1 gene expression: requirement of p38 MAPK (mitogen-activated protein kinase) activation but not of NF-kappaB (nuclear factor kappaB) inhibition. Biochem J (2004) 1.08

Low frequency of ras gene mutations in neuroblastomas, pheochromocytomas, and medullary thyroid cancers. Cancer Res (1991) 1.08

Cell lineage and differentiation state are primary determinants of MYCN gene expression and malignant potential in human neuroblastoma cells. Oncol Res (1997) 1.06

Neurofibromatosis type 1 and associated malignancies. Curr Neurol Neurosci Rep (2009) 1.03

Phosphorylation of neurofibromin by PKC is a possible molecular switch in EGF receptor signaling in neural cells. Oncogene (2006) 0.93

Regulation of the Ras-GTPase activating protein neurofibromin by C-tail phosphorylation: implications for protein kinase C/Ras/extracellular signal-regulated kinase 1/2 pathway signaling and neuronal differentiation. J Neurochem (2009) 0.88

Ras/MEK signaling suppresses Myc-dependent apoptosis in cells transformed by c-myc and activated ras. Oncogene (2000) 0.86

Contrasting levels of p21ras activation and expression of neurofibromin in peripheral primitive neuroectodermal tumour and neuroblastoma cells, and their response to retinoic acid. J Neurol Sci (1998) 0.77